Ovid Therapeutics Inc (OVID)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jeremy M. Levin
Employees:
60
1460 BROADWAY, SUITE 15044, NEW YORK, NY 10036
212-776-4381

Ovid Therapeutics Inc. develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome. OV329, a GABA aminotransferase inhibitor, and OV350, a small molecule for treating epilepsies.

Data derived from most recent annual or quarterly report
Market Cap 126.666 Million Shares Outstanding70.37 Million Avg 30-day Volume 65.484 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS2.32
Price to Revenue0.0 Debt to Equity0.0 EBITDA-68.58 Million
Price to Book Value0.9123 Operating Margin0.0 Enterprise Value-14.217 Million
Current Ratio20.869 EPS Growth-1.544 Quick Ratio20.477
1 Yr BETA 0.6296 52-week High/Low 3.6 / 1.41 Profit Margin0.0
Operating Cash Flow Growth-149.9996 Altman Z-Score-0.0924 Free Cash Flow to Firm -53.441 Million
View SEC Filings from OVID instead.

View recent insider trading info

Funds Holding OVID (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OVID

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-10:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-11:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-03:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-08-18:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    TARDIO JASON CHIEF OPERATING OFFICER

    • Officer
    0 2022-09-12 3

    TAKEDA PHARMACEUTICAL CO LTD

    TAKEDA PHARMACEUTICALS U.S.A., INC.

    • 10% Owner
    7,533,246 2022-07-01 1

    LEVIN JEREMY M CEO

    • Officer
    • Director
    • 10% Owner
    423,244 2022-04-08 2

    RONA JEFFREY A CBFO

    • Officer
    204,399 2022-04-08 2

    DUNCAN BARBARA GAYLE

    • Director
    21,347 2022-04-08 2

    FRIEDMAN BART

    • Director
    69,424 2022-04-08 2

    BERNSTEIN KAREN

    • Director
    69,424 2022-04-08 2

    PERONE THOMAS MICHAEL GENERAL COUNSEL, SECRETARY

    • Officer
    35,399 2022-04-08 2

    POOLE ROBERT MICHAEL

    • Director
    15,000 2022-02-03 1

    FITZGERALD KEVIN JOSEPH

    • Director
    15,000 2022-02-03 1

    RAKHIT AMIT PRESIDENT AND CMO

    • Officer
    817,806 2021-07-14 0

    WILLIAMS DOUGLAS E

    • Director
    1,750 2021-05-17 0

    DALY TIMOTHY EVP,FINANCE & CORP. CONTROLLER

    • Officer
    0 2020-12-17 0

    HAASNER DIRK SVP, GLOBAL REGULATORY AFFAIRS

    • Officer
    0 2020-12-17 0

    TAKEDA PHARMACEUTICAL CO LTD

    MILLENNIUM PHARMACEUTICALS INC

    • 10% Owner
    5,750,000 2019-10-08 1

    DURING MATTHEW PRESIDENT AND CSO

    • Officer
    • Director
    • 10% Owner
    0 2019-02-24 0

    WARD ANA SVP AND GENERAL COUNSEL

    • Officer
    0 2019-02-24 0

    WERBER YARON CBO, CFO, SEC. AND TREAS.

    • Officer
    0 2018-01-19 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    OVID THERAPEUTICS INC OVID 2022-11-25 22:15:03 UTC 2.9443 0.8757 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 21:45:04 UTC 2.9443 0.8757 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 21:15:03 UTC 2.9443 0.8757 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 20:45:03 UTC 2.9443 0.8757 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 20:15:03 UTC 2.9443 0.8757 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 19:45:04 UTC 2.9443 0.8757 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 19:15:03 UTC 2.9443 0.8757 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 18:45:03 UTC 2.9443 0.8757 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 18:15:03 UTC 2.9443 0.8757 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 17:45:04 UTC 2.9443 0.8757 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 17:15:03 UTC 2.9443 0.8757 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 16:45:04 UTC 3.0261 0.7939 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 16:15:03 UTC 3.0261 0.7939 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 15:45:03 UTC 3.0261 0.7939 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 15:15:03 UTC 3.0261 0.7939 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 14:45:04 UTC 3.0261 0.7939 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 14:15:04 UTC 3.0261 0.7939 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 13:45:03 UTC 3.0261 0.7939 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 13:15:03 UTC 3.0261 0.7939 350000
    OVID THERAPEUTICS INC OVID 2022-11-25 12:45:03 UTC 3.0261 0.7939 350000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund OVID -2700.0 shares, $-4968.0 2022-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments